Advertisement

Topics

CStone to Start Combo Trial of its PD-L1 with Bayer's Stivarga for Gastric Cancer

05:33 EDT 12 Jun 2019 | ChinaBio Today

CStone Pharma of Suzhou will test its PD-L1 monoclonal antibody in combination with Bayer Healthcare's Stivarga® (regorafenib) as a treatment for multiple cancers including gastric cancer. Stivarga is a multi-kinase inhibitor that targets VEGFR, FGFR, CSF1R, etc. The two companies described the collaboration as a global effort with a China emphasis. CStone will be the study sponsor and Bayer will provide regorafenib throughout the clinical trial program. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

Original Article: CStone to Start Combo Trial of its PD-L1 with Bayer's Stivarga for Gastric Cancer

NEXT ARTICLE

More From BioPortfolio on "CStone to Start Combo Trial of its PD-L1 with Bayer's Stivarga for Gastric Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...